the company, the net profit of the company will be Baht 1,081 million. This is an increase from Q1/2019 by Baht 139 million or 15%, and an increase from Q2/2018 by Baht 28 million. Both GPSC and GLOW
1,494 8% EBITDA Bio-Based Product Business4/ 113 179 59 -48% -67% 259 238 -8% EBITDA Resource Business5/ 59 133 93 58% -30% 81 226 181% EBITDA Others 6/ (25) (25) (12) 54% 53% (25) (37) -48% Profit
Commission (SEC). An English version of the MD&A has been prepared from the Thai version. In the event of a conflict or a difference in interpretation between the two languages, the Thai version shall prevail
) 1,230.51 274.45 Gross Profit (Loss) 163.14 (24.34) 187.48 770.25 Sales & Administration Expenses and Financial Cost and Tax Expense (32.44) (20.02) 12.42 62.04 Net Profit (Loss) 132.25 (43.62) 175.87 403.19
) 1,230.51 274.45 Gross Profit (Loss) 163.14 (24.34) 187.48 770.25 Sales & Administration Expenses and Financial Cost and Tax Expense (32.44) (20.02) 12.42 62.04 Net Profit (Loss) 132.25 (43.62) 175.87 403.19
increased Baht 2,839 million or 134% from Q1/2019. For Q1/2020, the Company’s Adjusted Net Income, which is the net profit excluding the fair value of intangible asset from the acquisition of GLOW was Baht
2019 of 26.14%, has resulted in the company being able to recognize net profit for the company at 95.25% after the 22nd May 2019. Consequently, on the 19th June 2019, the Board of Directors has passed
net profit of THB 126 mn). • Excluding the non-recurring items net profit contributed by GLAND amounted to THB 74 mn (for the first six months of 2019, net profit of THB 141 mn). The difference versus
498 mn with immaterial impact to CPN’s consolidated net profit. The difference versus GLAND’s reported statement of comprehensive income is down to the difference in accounting treatment of investment
498 mn with immaterial impact to CPN’s consolidated net profit. The difference versus GLAND’s reported statement of comprehensive income is down to the difference in accounting treatment of investment